Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Shares Issued: 2017-2025

Historic Shares Issued for Seres Therapeutics (MCRB) over the last 3 years, with Sep 2025 value amounting to $46,000.

  • Seres Therapeutics' Shares Issued fell 65.67% to $46,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $717,000, marking a year-over-year decrease of 72.82%. This contributed to the annual value of $487,000 for FY2024, which is 77.36% down from last year.
  • Latest data reveals that Seres Therapeutics reported Shares Issued of $46,000 as of Q3 2025, which was down 75.00% from $184,000 recorded in Q1 2025.
  • Seres Therapeutics' 5-year Shares Issued high stood at $99.1 million for Q3 2022, and its period low was -$3.3 million during Q4 2022.
  • Over the past 3 years, Seres Therapeutics' median Shares Issued value was $268,500 (recorded in 2024), while the average stood at $478,000.
  • Examining YoY changes over the last 5 years, Seres Therapeutics' Shares Issued showed a top increase of 56,858.62% in 2022 and a maximum decrease of 2,051.79% in 2022.
  • Seres Therapeutics' Shares Issued (Quarterly) stood at $168,000 in 2021, then slumped by 2,051.79% to -$3.3 million in 2022, then crashed by 99.07% to $922,000 in 2023, then slumped by 85.47% to $134,000 in 2024, then crashed by 65.67% to $46,000 in 2025.
  • Its Shares Issued was $46,000 in Q3 2025, compared to $184,000 in Q1 2025 and $134,000 in Q3 2024.